CAMP4 Therapeutics (NASDAQ:CAMP) Stock Picked Up by Analysts at Raymond James Financial

Stock analysts at Raymond James Financial started coverage on shares of CAMP4 Therapeutics (NASDAQ:CAMP) in a research report issued on Friday, MarketBeat reports. The firm set a “strong-buy” rating and a $10.00 price target on the Wireless communications provider’s stock. Raymond James Financial‘s target price suggests a potential upside of 194.99% from the company’s previous close.

Other research analysts also recently issued research reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of CAMP4 Therapeutics in a research note on Tuesday, September 29th. Chardan Capital lowered their price target on shares of CAMP4 Therapeutics from $6.50 to $6.00 and set a “buy” rating for the company in a report on Tuesday, September 29th. Weiss Ratings raised shares of CAMP4 Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. Oppenheimer began coverage on shares of CAMP4 Therapeutics in a report on Monday, October 5th. They issued an “outperform” rating and a $15.00 price objective on the stock. Finally, Wall Street Zen lowered shares of CAMP4 Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 10th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CAMP4 Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $10.44.

CAMP4 Therapeutics Stock Up 3.0%

CAMP stock opened at $3.39 on Friday. The business’s 50-day moving average is $4.04 and its two-hundred day moving average is $4.14. CAMP4 Therapeutics has a 1 year low of $2.90 and a 1 year high of $7.75.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings data on Thursday, August 13th. The Wireless communications provider reported ($0.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.34). CAMP4 Therapeutics had a negative net margin of 2,543.74% and a negative return on equity of 252.79%. The company had revenue of $1.78 million during the quarter. On average, equities research analysts predict that CAMP4 Therapeutics will post -0.66 EPS for the current fiscal year.

Insider Transactions at CAMP4 Therapeutics

In other news, Director Andrew Schwab sold 400,000 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $4.04, for a total transaction of $1,616,000.00. Following the sale, the director owned 2,033,270 shares of the company’s stock, valued at approximately $8,214,410.80. This trade represents a 16.44% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Kelly Gold bought 10,000 shares of the firm’s stock in a transaction that occurred on Monday, August 31st. The shares were acquired at an average price of $3.96 per share, with a total value of $39,600.00. Following the purchase, the chief financial officer owned 10,000 shares of the company’s stock, valued at $39,600. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders have acquired 46,031 shares of company stock valued at $99,051 and have sold 593,613 shares valued at $2,504,037. Corporate insiders own 21.69% of the company’s stock.

Institutional Trading of CAMP4 Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CAMP. Bank of America Corp DE acquired a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at $78,000. Deutsche Bank AG purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at $138,000. Bank of New York Mellon Corp purchased a new position in shares of CAMP4 Therapeutics in the 2nd quarter valued at $365,000. SummitTX Capital L.P. purchased a new position in shares of CAMP4 Therapeutics in the 1st quarter valued at $1,497,000. Finally, BlackRock Inc. acquired a new stake in CAMP4 Therapeutics during the 2nd quarter worth $7,185,000.

About CAMP4 Therapeutics

CAMP4 Therapeutics Corporation is a clinical-stage biotechnology company focused on developing RNA-based medicines for genetic diseases caused by insufficient production of essential proteins. The company’s approach is designed to increase expression of a patient’s existing genes rather than replace or edit them.

CAMP4 uses its RegRNA platform to identify regulatory elements in messenger RNA and develop RNA activators, including small activating RNAs, that may stimulate production of targeted proteins.